Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

GlobeNewswire July 24, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Newsfile July 23, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 20, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 19, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

PR Newswire July 17, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 13, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 11, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 10, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 10, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Newsfile July 8, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 8, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 7, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Newsfile July 7, 2023

Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering

GlobeNewswire July 6, 2023

Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

GlobeNewswire July 5, 2023

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

GlobeNewswire June 28, 2023

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

GlobeNewswire June 27, 2023

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

GlobeNewswire June 20, 2023

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

GlobeNewswire May 30, 2023

Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

Accesswire April 27, 2023